BIONOMICS
Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small molecule product development programs in the areas of cancer, anxiety, epilepsy, and multiple sclerosis. The company develops its lead cancer compound, BNC 105, for the treatment of solid tumors, such as breast, lung, colon, and prostate cancers. BNC 105 is a member of the class of compounds, known as vascular disruption agents or VDAs, which... shut down the blood supply within a tumor, starving the tumor and preventing its continued growth. The company has commercial partnerships with Genmab A/S; Athena Diagnostics; Laboratory Corporation of America; and Genetic Technologies, Ltd. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.
BIONOMICS
Industry:
Biotechnology Health Diagnostics Medical
Founded:
1999-01-01
Address:
Thebarton, South Australia, Australia
Country:
Australia
Website Url:
http://www.bionomics.com.au
Total Employee:
11+
Status:
Active
Contact:
61 8 8354 6100
Email Addresses:
[email protected]
Total Funding:
38.64 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Vulcan Biosciences
Vulcan Biosciences commercializes a therapy for treating multiple sclerosis (MS), a debilitating disease of the central nervous system.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-09-23 | Prestwick Chemical | Prestwick Chemical acquired by Bionomics | N/A |
| 2012-09-17 | Eclipse Therapeutics | Eclipse Therapeutics acquired by Bionomics | 10 M USD |
| 2005-05-24 | Iliad Chemicals Pty | Iliad Chemicals Pty acquired by Bionomics | 6.1 M AUD |
Investors List
Novamind
Novamind investment in Post-IPO Equity - Bionomics
Start-up Australia Ventures
Start-up Australia Ventures investment in Post-IPO Equity - Bionomics
Official Site Inspections
http://www.bionomics.com.au Semrush global rank: 6.43 M Semrush visits lastest month: 1.02 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Bionomics"
Bionomics Corporate Update
Bionomics is an Advanced Clinical Stage, CNS-focused Biotech Company with Multiple Upcoming Value-Creating Milestones Leading expertise in ion channel targeting, advancing a pipeline of …See details»
Bionomics - Crunchbase Company Profile & Funding
Contact Email [email protected]; Phone Number 61 8 8354 6100; Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small …See details»
Contact Us | Bionomics – Clinical-stage biopharmaceutical company
Contact us details for Bionomics, a global, clinical-stage biopharmaceutical company based in Adelaide, South Australia. ... Email: [email protected]. Stock Exchange Listing ASX …See details»
Bionomics Announces Intention to Delist from the Australian …
Jul 25, 2023 Bionomics’s pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. …See details»
Bionomics Ltd - LinkedIn
Bionomics Ltd | 2,211 followers on LinkedIn. Developing novel drug candidates to transform the lives of patients with anxiety and stressor-related CNS disorders | Bionomics (Nasdaq: BNOX, …See details»
Bionomics Limited - Company Profile Report | IBISWorld
Jun 30, 2020 Bionomics is a public biopharmaceutical company that develops modulator drugs that help patients with central nervous system disorders. The Company's main modulator drug …See details»
Bionomics’ Half-Year Report | Bionomics Ltd
Beyond BNC210, Bionomics has a strategic partnership with Merck & Co, Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the …See details»
Results of Scheme Meeting - GlobeNewswire
Dec 12, 2024 About Bionomics Limited . Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel …See details»
Developing treatments for patients with underserved CNS
Bionomics is an Advanced Clinical Stage CNS-focused Biotech Company with Multiple Value-Creating Milestones Leading expertise in ion channel targeting, advancing a pipeline of best-in …See details»
Bionomics Provides an Update on Re-domiciliation via …
Nov 8, 2024 ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first ...See details»
Bionomics Reminds Shareholders to Cast their Vote for
Dec 2, 2024 Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. …See details»
Bionomics Announces Supreme Court of New South Wales
Dec 16, 2024 About Bionomics Limited Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel …See details»
Bionomics Limited - Cruelty Free Investing
Bionomics Ltd operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a pipeline of novel therapeutic ion channel targeting drug candidates to improve …See details»
Bionomics to Present at the ThinkEquity Conference
Oct 23, 2024 Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. …See details»
Executive Leadership | Bionomics – biopharmaceuticals
She joined Bionomics Limited in 2008 to lead the early clinical development program for BNC210, a small molecule with therapeutic potential for anxiety disorders, and trauma and stressor …See details»
2021 Annual Report - Bionomics
Bionomics Limited | 200 Greenhill Road, Eastwood, South Australia, +61 8 8150 7400, ABN: 53 075 582 740 . ABN 53 075 582 740 . ASX ANNOUNCEMENT . 29 OCTOBER 2021 . 2021 …See details»
2021 Annual Report - Bionomics Ltd
Oct 29, 2021 News Release Detail 2021 Annual Report. October 29, 2021 at 8:54 AM AEDTSee details»
Bionomics Company Profile 2024: Stock Performance & Earnings
Bionomics General Information Description. Developer of therapeutics designed to treat cancer and diseases of the central nervous system. The company focuses on developing novel, first …See details»
Pipeline | Bionomics – Clinical-stage biopharmaceutical company
Bionomics has a CNS focused pipeline led by its programs in Social Anxiety Disorder (“SAD”) and Post-Traumatic Stress Disorder (“PTSD”), both of which received the U.S Food and Drug …See details»